PharmatrophiX (PTX) is a privately held biopharmaceutical company focused on the development of disease-modifying small molecule drugs targeting mechanisms underlying neurodegenerative and other disorders. PTX is operated as a virtual biotech company in Menlo Park, CA executing drug development through contracted work. This virtual model is recognized as an effective way of minimizing overhead costs while efficiently achieving drug development milestones. PTX was founded in 2005 by Frank M. Longo, MD, PhD during his tenure at UNC - Chapel Hill. He serves as Chairman of the Board of PTX and as a consultant. Seed funding and additional corporate funding has been provided by the peer-reviewed biotech support program of the Alzheimer's Drug Development Foundation (ADDF).